Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients.
about
Polypharmacy in the HIV-infected older adult population.Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan childrenMaraviroc: in vitro assessment of drug-drug interaction potentialArtemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implicationsEffect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review.Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adultsSynthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR).The effect of HIV on malaria in the context of the current standard of care for HIV-infected populations in Africa.Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavirMethadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamicsEfavirenz: a review.The role of cytochrome P450 in antiretroviral drug interactions.Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycinThe impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC.Pharmacologic consideration for the use of antiretroviral agents in the elderly.Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.Efavirenz: a decade of clinical experience in the treatment of HIV.The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems.Induction of cytochrome P450 enzymes: a view on human in vivo findings.Pharmacological management of cardiovascular conditions and diabetes in older adults with HIV infection.Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.Effect of Efavirenz on Endogenous Progesterone Concentrations and Contraceptive Outcomes among Ugandan HIV Infected Women Coadministering Ethinylestradiol/LevonorgestrelPharmacokinetic interactions of efavirenz and voriconazole in healthy volunteersInhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase.Genetic variations of the xenoreceptors NR1I2 and NR1I3 and their effect on drug disposition and response variability.Semisimultaneous Midazolam Administration to Evaluate the Time Course of CYP3A Activation by a Single Oral Dose of Efavirenz.Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice.Impact of efavirenz, ritonavir-boosted lopinavir and nevirapine based antiretroviral regimens on the pharmacokinetics of lumefantrine and safety of artemether-lumefantrine in -negative HIV-infected Malawian adults stabilized on antiretroviral therapy
P2860
Q34037407-BF3EC59B-3B58-49EC-8BBC-E3259A2491BCQ34137766-C24930B5-5D1D-4A17-9F52-78E8CD566308Q34594626-1F450248-DBDB-4F2F-B92A-577907580C4BQ35286119-5707A81C-6FD3-4D15-88E2-AF64119B94E6Q35827661-D708EE8D-4EC5-4CCF-AD8B-051FB5C7872AQ36273788-4B39039C-D7F8-4A6A-BD4B-7DB33E44DBADQ36300127-4F2AD3D7-6A64-4514-A603-5377331DC265Q36473477-49F8BA5F-B29A-4EFC-8A5B-E38C7E2EC36BQ36504556-60339BB6-97D4-4C0F-8675-058306250927Q36544977-03223F99-0B4D-441F-8CBD-45511CA715DFQ36593838-3F03094B-9B86-4368-9806-CFE51DC2CE3FQ36637864-A57136AC-666F-4DC1-8AAF-4C7B915CC561Q36693543-9B0E80F6-53E3-4B7A-AC5F-2693C27AF89AQ36787311-21D92FF9-29FF-4895-AC1E-E17BE64E75AAQ36909336-B6C3864C-BCEB-43DD-A253-32C460C46831Q37016344-6B6D608F-0F05-4F9B-BCB1-16F5D53C90D7Q37230649-F55B9165-6A49-49BA-A70D-26DED2E75434Q37277510-0DEFD9F3-E7BC-4553-9B0D-659F00B23F17Q37369341-2D55C364-5366-43A5-9CFB-CE1F0D8E46EFQ37383949-4E9EB765-28A1-4632-9EF5-D1A46BEABA8EQ37836908-D1C7A3D9-D519-48C7-B58C-BD257048B07AQ38028549-85383FDC-7FDD-42ED-B51C-B3FCBE06F128Q38057372-9712AFF9-38DC-4D91-ADC6-9B7B7E402649Q38172305-AB85F973-0ED9-4255-B887-232B9337D71EQ38653256-EB6FB69F-BEDD-40C7-AA9F-7085A088D16BQ38849112-8CA0D772-E423-429C-ADA6-632BFBA48013Q42283777-2A04DC1D-4312-47CC-97A6-BD4145E92DD1Q42931493-305FCE5B-DB12-4B30-BF3B-72CB159830B8Q49332317-76AC3CD8-B10B-4C63-AF22-E15694CB56ACQ50894716-6CBA464E-6B57-46A5-98DE-2C8FCC40AB05Q51051365-6BA076EC-8419-403E-BA9C-834CADAE7829Q54267469-B7958347-9AD6-4821-8045-2097F1DEA700Q56339581-9C27EA7A-30EE-4FDD-A9CF-F92EE7E924D6
P2860
Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Variations of CYP3A activity i ...... nt in HIV-1 infected patients.
@en
Variations of CYP3A activity i ...... nt in HIV-1 infected patients.
@nl
type
label
Variations of CYP3A activity i ...... nt in HIV-1 infected patients.
@en
Variations of CYP3A activity i ...... nt in HIV-1 infected patients.
@nl
prefLabel
Variations of CYP3A activity i ...... nt in HIV-1 infected patients.
@en
Variations of CYP3A activity i ...... nt in HIV-1 infected patients.
@nl
P2093
P50
P1476
Variations of CYP3A activity i ...... nt in HIV-1 infected patients.
@en
P2093
Amalio Telenti
Catia Marzolini
Kerry Powell Golay
Pierre Baumann
P2888
P304
P356
10.1007/S00228-004-0855-8
P577
2005-01-19T00:00:00Z
P5875
P6179
1029787343